Sodium Glucose Co-Transporter Inhibition in Acute Heart Failure – An In-Depth Review DOI Creative Commons
Joey Mercier, Aditya Sharma,

Magdaline Zawadka

et al.

CJC Open, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease? DOI
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 7, 2025

Introduction Major global guidelines currently recommend sodium-glucose co-transporter-2 inhibitors (SGLT-2i) as the first-line agents in people with type 2 diabetes (T2D) who have either established cardiovascular disease (eCVD), heart failure (HF), or chronic kidney (CKD), regardless of baseline glycated hemoglobin. Moreover, SGLT-2i are included guideline-directed medical therapy one pillars for HF and CKD, T2D. These recommendations based on positive cardio-renal outcomes from several randomized controlled trials (RCTs).

Language: Английский

Citations

0
Sodium Glucose Co-Transporter Inhibition in Acute Heart Failure – An In-Depth Review DOI Creative Commons
Joey Mercier, Aditya Sharma,

Magdaline Zawadka

et al.

CJC Open, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

0